1. Home
  2. VEEV vs RPRX Comparison

VEEV vs RPRX Comparison

Compare VEEV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veeva Systems Inc.

VEEV

Veeva Systems Inc.

HOLD

Current Price

$172.55

Market Cap

27.4B

Sector

Technology

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$55.89

Market Cap

22.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VEEV
RPRX
Founded
2007
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4B
22.0B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
VEEV
RPRX
Price
$172.55
$55.89
Analyst Decision
Buy
Strong Buy
Analyst Count
25
5
Target Price
$280.42
$51.40
AVG Volume (30 Days)
2.4M
3.1M
Earning Date
05-27-2026
05-06-2026
Dividend Yield
N/A
1.90%
EPS Growth
25.93
N/A
EPS
5.44
0.67
Revenue
$1,104,081,000.00
$2,378,193,000.00
Revenue This Year
$14.42
$38.63
Revenue Next Year
$12.17
$4.73
P/E Ratio
$32.67
$82.19
Revenue Growth
28.05
5.06
52 Week Low
$148.05
$33.37
52 Week High
$310.50
$56.01

Technical Indicators

Market Signals
Indicator
VEEV
RPRX
Relative Strength Index (RSI) 54.99 67.93
Support Level $172.59 $35.35
Resistance Level $184.71 N/A
Average True Range (ATR) 8.14 1.16
MACD 1.98 0.02
Stochastic Oscillator 52.14 93.81

Price Performance

Historical Comparison
VEEV
RPRX

About VEEV Veeva Systems Inc.

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: